Skip to main content

Table 19 The cost-effectiveness analysis in the 24-month period (the incidence of diabetes)

From: The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design

Group C (yuan) E (%) C/E ΔC/ΔE
The treatment group 44911142.2 20.3 2212371.5 −333624.6
The control group 40740835.2 32.8 1242098.6